List of Excipients in Branded Drug CARBON DIOXIDE AIR MIXTURE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
General Air Service & Supply Co	CARBON DIOXIDE AIR MIXTURE	carbon dioxide air mixture	21220-157	OXYGEN

# Carbon Dioxide-Air Mixture: Excipient Strategy, Regulatory Pathway, Patent Risk and Commercial Opportunities

Last updated: August 30, 2026

Carbon dioxide-air mixture is a medical-gas product rather than a conventional pharmaceutical formulation. Its commercial value depends on gas composition, intended use, delivery hardware, container system, and manufacturing controls. The strongest opportunities are in procedure-specific gas blends, validated delivery systems, hospital supply contracts, and specialty diagnostic or respiratory applications. Traditional excipient patenting has limited value because the product contains simple gases and has few formulation variables.

What is carbon dioxide-air mixture used for?

Carbon dioxide-air mixtures can be used as medical gases for controlled administration of carbon dioxide, respiratory stimulation, diagnostic procedures, or tissue and cavity insufflation, depending on the concentration and route of administration.

The product should be analyzed through four variables:

Variable	Commercial significance
Carbon dioxide concentration	Determines pharmacology, tolerability, labeling, and clinical use
Balance gas	Air, oxygen, nitrogen, or another carrier changes safety and performance
Route of administration	Inhalation, insufflation, or external procedural use creates different regulatory requirements
Delivery system	Cylinders, bulk tanks, regulators, masks, ventilators, and procedure-specific devices affect product differentiation

A carbon dioxide-air mixture is not interchangeable with carbogen. Carbogen normally refers to a carbon dioxide and oxygen mixture, commonly 5% carbon dioxide and 95% oxygen. A carbon dioxide-air mixture contains atmospheric air as the balance gas and therefore has a materially different oxygen concentration and clinical profile.

Is carbon dioxide-air mixture an excipient or an active pharmaceutical ingredient?

In most pharmaceutical applications, carbon dioxide is treated as an active medicinal gas when it produces the intended physiological or procedural effect. The air component may function as a carrier gas, diluent, or formulation matrix, but it is not necessarily an excipient in the conventional tablet, capsule, or injectable sense.

The classification depends on the labeled use:

• If carbon dioxide produces the therapeutic or diagnostic effect, it is the active ingredient.
• If carbon dioxide is used only to adjust pH, displace oxygen, or pressurize a container, its regulatory role may be ancillary.
• If air is used as the carrier for administration, it is usually a formulation component or vehicle rather than a conventional pharmaceutical excipient.
• If the mixture is used to operate a device or perform a procedure without a direct medicinal claim, the product may fall partly within medical-device or procedural-gas regulation.

The regulatory dossier should therefore identify each component by function rather than labeling both gases as excipients. This distinction affects active-ingredient specifications, stability testing, clinical justification, labeling, and patent strategy.

What excipient strategy applies to carbon dioxide-air mixture?

The appropriate excipient strategy is based on purity, compatibility, delivery, and container integrity. Conventional excipients such as preservatives, buffers, surfactants, or stabilizers generally have no role in a compressed-gas product.

Gas composition strategy

The primary formulation variable is the carbon dioxide concentration. A sponsor can develop:

1. A single fixed concentration for a defined indication.
2. A concentration range supported by clinical or procedural data.
3. Several strengths for different patient populations or procedures.
4. A device-controlled dilution system that mixes concentrated carbon dioxide with medical air at the point of use.

Fixed pre-mixed cylinders simplify regulatory control and reduce operator error. Point-of-use mixing can reduce inventory requirements but creates greater device validation, calibration, and human-factors obligations.

Carrier-gas strategy

Air is commercially attractive because it is familiar, inexpensive, and broadly available. It also limits the oxygen enrichment associated with carbon dioxide-oxygen mixtures. The disadvantages are greater variability in oxygen content unless the air is manufactured to a defined medical specification, and potential incompatibility with uses requiring controlled oxygen delivery.

Potential carrier options include:

Carrier gas	Potential advantage	Principal limitation
Medical air	Familiar clinical profile and broad hospital infrastructure	Requires tight control of oxygen, moisture, hydrocarbons, and contaminants
Nitrogen	Chemically inert carrier and low oxygen content	May not match intended respiratory or procedural use
Oxygen	Supports carbogen-type applications	Creates a different product, safety profile, and clinical rationale
Helium-containing mixture	May alter flow characteristics	Higher cost and narrower use case

Moisture and contamination control

Moisture is a major quality consideration. Water can affect cylinder valves, regulators, pressure control, corrosion risk, and microbial control in downstream systems. The manufacturing process should control:

• Water vapor
• Carbon monoxide
• Nitrogen oxides
• Hydrocarbons
• Particulate matter
• Microbial contamination where applicable
• Cross-contamination from other medical gases

The applicable gas monographs and national standards should define release specifications. USP-NF includes quality standards for medical gases, while European products generally rely on European Pharmacopoeia requirements and national authorization standards.[1,2]

Container and closure system

For a compressed-gas product, the cylinder and valve assembly perform the role that a primary container and closure perform for a liquid drug. Commercial differentiation can come from:

• Residual-pressure retention
• Valve design
• Integrated pressure regulation
• Tamper evidence
• Barcode and serialization
• Low-residual-volume performance
• Compatibility with anesthesia and respiratory equipment
• Reduced cylinder weight
• Refillable versus single-use architecture

Container closure integrity should be assessed through pressure-retention studies, leak testing, valve-cycle testing, transport simulation, and compatibility testing with the intended regulator and administration device.

What FDA regulatory pathway applies to carbon dioxide-air mixture?

In the United States, medical gases are regulated as drugs when they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body. FDA established a dedicated current good manufacturing practice framework for medical gases in 21 C.F.R. Part 213.[3]

The regulatory pathway depends on whether the product is:

• A new drug with a new concentration, indication, or route;
• A duplicate or equivalent medical gas;
• A reformulated or repackaged gas;
• A gas administered through a combination product or device.

Key FDA requirements include:

Area	Expected requirement
Chemistry, manufacturing, and controls	Defined gas composition, impurity limits, filling controls, batch release, and container specifications
Facility controls	Segregation of gases, validated filling equipment, cylinder identification, and pressure controls
Labeling	Concentration, intended use, warnings, storage, administration instructions, and cylinder handling
Stability	Composition stability, pressure retention, valve performance, and transport conditions
Device interface	Compatibility with masks, regulators, ventilators, insufflation equipment, or other delivery systems
Pharmacovigilance	Adverse-event reporting and complaint handling under applicable FDA rules

FDA’s medical-gas framework does not eliminate the need to establish a lawful marketing basis. A product with a new clinical claim, novel concentration, or materially different delivery system may require a new drug application or another FDA-recognized pathway.[3,4]

What is the Orange Book status of carbon dioxide-air mixture?

Orange Book status must be assessed by product-specific application and strength. A generic reference cannot be assumed from the gas name alone.

For a listed prescription product, the relevant questions are:

• Is the product listed as a finished drug?
• Is the application active?
• Are patents or exclusivity periods listed?
• Does the product have an established route and strength?
• Is an abbreviated new drug application pathway available?
• Does the intended use create a new drug claim outside the reference product’s labeling?

Simple medical gases often have limited patent exposure compared with complex small-molecule products. Their commercial barriers more often arise from FDA manufacturing requirements, hospital qualification, reliable supply, cylinder logistics, and device compatibility.

The Orange Book should be checked at the product and application level rather than by searching only for the chemical description. FDA identifies approved drug products, patent listings, and exclusivity through the Orange Book database.[5]

When does carbon dioxide-air mixture lose exclusivity?

Exclusivity is not determined by a single expiration date for the gas itself. The relevant timing depends on the legal basis for market protection.

Protection type	Relevance to carbon dioxide-air mixture
New chemical entity exclusivity	Usually limited relevance because carbon dioxide and air are established substances
New drug exclusivity	Possible if a new product, indication, or regulatory basis qualifies
Orphan-drug exclusivity	Possible only for an eligible rare-disease indication
Pediatric exclusivity	Possible if awarded under FDA requirements
Method-of-use patent	Could protect a specific concentration, procedure, or patient population
Formulation patent	More likely to cover a packaged composition, mixing ratio, or delivery architecture
Device patent	Could protect regulators, mixers, valves, sensors, or procedure-specific systems
Trade secret	May protect filling processes, quality systems, or supply-chain controls

Patent term generally runs 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory provisions.[6] For a basic gas mixture, the strongest enforceable rights are more likely to be narrow and implementation-focused than composition-focused.

What patents protect carbon dioxide-air mixture?

The core gases are established substances and are difficult to protect through broad composition claims. A commercially meaningful estate would more likely include the following claim categories.

Concentration and therapeutic-use claims

A patent may claim administration of a specified carbon dioxide concentration for:

• Respiratory stimulation
• Controlled exposure protocols
• Vascular or neurological testing
• Tissue or cavity insufflation
• Diagnostic provocation
• Adjunctive treatment with another therapy

Method-of-use claims require careful analysis of the approved label, clinical protocol, and infringement evidence. A broad claim to administering carbon dioxide in air may face prior-art challenges if similar gas mixtures and uses were previously disclosed.

Formulation and mixture claims

Potential claim limitations include:

• Defined carbon dioxide concentration
• Medical-air specifications
• Maximum moisture level
• Defined oxygen range
• Impurity thresholds
• Pressure range
• Single-cylinder composition
• Premixed versus point-of-use mixing

These claims can protect a commercial specification even where the ingredients themselves are old. Their strength depends on whether the parameters are technically meaningful and non-obvious.

Packaging and delivery claims

The most defensible commercial patents may cover:

• A pressure-regulated cylinder
• A calibrated gas blender
• Automatic concentration monitoring
• A fail-safe valve
• A connection preventing attachment to the wrong device
• A disposable patient interface
• A system that compensates for pressure or temperature
• A digital record of dose and exposure

Such claims can create competitive protection even when a rival can legally manufacture the same gas composition.

How strong is the patent estate for carbon dioxide-air mixture?

The composition-level patent estate is likely weak for a basic premixed product because the ingredients are known and the number of meaningful formulation variables is small. The overall commercial estate can be stronger if it includes validated delivery hardware, narrow medical indications, and manufacturing controls that produce measurable clinical or safety benefits.

Estate component	Likely strength	Business value
Broad claim to carbon dioxide in air	Low	Limited exclusivity
Narrow concentration range	Low to moderate	Supports product differentiation
Specific method of use	Moderate	Can protect targeted indications
Cylinder and valve system	Moderate to strong	Creates switching costs
Automated mixing and monitoring	Moderate to strong	Supports premium pricing
Manufacturing process	Moderate	May be difficult to reverse engineer
Trade-secret quality controls	Moderate	Useful where patent disclosure is undesirable

A freedom-to-operate review should search U.S., European, Japanese, Chinese, and international patent records for carbon dioxide inhalation, medical-gas mixing, insufflation, gas blenders, regulators, and sensor-controlled delivery. Patent families should be grouped by priority date, legal status, continuation practice, and claim scope.

What commercial opportunities exist for carbon dioxide-air mixture?

Hospital and procedural supply

Hospitals purchase medical gases through contracted supply arrangements. The opportunity is strongest where the product reduces preparation time, limits cylinder handling, or integrates with existing equipment.

A supplier can compete through:

• Reliable regional filling capacity
• Standardized cylinder sizes
• Automated replenishment
• Point-of-care inventory tracking
• Compatible regulators
• Procedure-specific kits
• Lower total cost of ownership

Device-linked products

A gas-only product is relatively easy to substitute. A gas-plus-device platform can support higher margins and stronger customer retention.

Potential offerings include:

• Preconfigured gas cylinders and regulators
• Smart gas mixers
• Single-use tubing and patient interfaces
• Concentration sensors
• Procedure-specific delivery carts
• Software-controlled exposure systems
• Disposable sterile or low-bioburden administration sets

Diagnostic and research markets

Controlled carbon dioxide exposure is relevant to physiology research, respiratory testing, vascular studies, and specialized laboratory protocols. These markets are smaller than general hospital gas supply but may tolerate higher prices when the product includes calibration, documentation, and technical support.

International markets

Geographic expansion requires country-specific analysis of:

• Medicinal-gas authorization
• Pharmacopeial compliance
• Cylinder transport rules
• Pressure-vessel certification
• Good manufacturing practice inspection
• Medical-device registration
• Local-language labeling
• Import and wholesale licensing

The European Union generally treats medicinal gases as medicinal products under Directive 2001/83/EC, with national authorization procedures and European Pharmacopoeia standards applying to quality requirements.[7] The United Kingdom, Canada, Australia, and Japan use related but distinct frameworks.

Which companies are challenging the market?

The competitive field includes three groups:

1. Large industrial-gas companies with bulk production, cylinder networks, and hospital contracts.
2. Specialty medical-gas manufacturers that compete through local filling and distribution.
3. Device companies that control the administration interface and may bundle gas supply with equipment.

Competitive strength is determined less by the carbon dioxide molecule than by filling infrastructure, regulatory history, cylinder ownership, delivery reliability, and hospital contracting. Device manufacturers can exert leverage if their systems require proprietary connections or validated gas specifications.

What generic entry risks exist?

Generic or copy-product entry risk is high for an unprotected premixed gas with a standard cylinder and no differentiated indication. The principal risks include:

• Competing medical-gas suppliers using equivalent specifications
• Hospital tenders shifting volume to the lowest qualified supplier
• Private-label distribution
• Local gas producers entering regional markets
• Device manufacturers qualifying multiple gas suppliers
• Regulatory approval of an equivalent product

Risk falls when the sponsor has:

• A protected clinical indication
• A patented delivery system
• Exclusive device compatibility
• A validated concentration-monitoring platform
• Long-term hospital contracts
• Proprietary filling and release controls
• High switching costs from installed equipment

A generic launch can occur without copying the branded cylinder or device if the competitor supplies an equivalent gas composition through a compatible system. Product labeling and intended use should therefore be analyzed alongside patent claims.

What litigation and settlement issues affect the product?

There is no general presumption that a carbon dioxide-air mixture has active patent litigation. Litigation exposure must be assessed by product, sponsor, indication, and delivery system.

The most likely disputes would involve:

• Patent infringement involving a specific concentration or treatment method
• Device patents covering gas mixing or delivery
• Trade-secret claims involving filling or quality-control procedures
• False or misleading equivalence claims
• Cylinder ownership and recovery
• Supply-contract exclusivity
• Regulatory disputes over labeling or intended use

Paragraph IV litigation is more relevant if an innovator product has an FDA-approved application with Orange Book-listed patents and a generic applicant files an abbreviated application. For a basic medical gas, the more likely commercial pathway may involve a competing application, product listing, or direct approval route rather than conventional small-molecule generic litigation.[3,5]

How should a sponsor build a defensible commercial strategy?

The strongest strategy is to treat the gas as one component of a regulated delivery platform.

A practical sequence is:

1. Define the exact concentration, carrier-gas specification, route, and indication.
2. Select a fixed premix or validated point-of-use mixing architecture.
3. Establish USP, Ph. Eur., or equivalent release standards.
4. Develop a cylinder, valve, regulator, and delivery-system compatibility package.
5. File patents before public clinical or commercial disclosure.
6. Separate broad commercial claims from narrower fallback claims.
7. Generate clinical or procedural data tied to the selected concentration.
8. Obtain regulatory clearance for the gas and any combination-product elements.
9. Secure hospital, distributor, and cylinder-logistics agreements.
10. Build a second-source manufacturing network to reduce supply risk.

The most valuable intellectual property is likely to cover a defined medical use, a controlled delivery system, and a measurable safety or performance improvement. A patent directed only to the existence of carbon dioxide mixed with air is unlikely to create durable market exclusivity.

Key Takeaways

• Carbon dioxide-air mixture is primarily a medical-gas product, not a conventional excipient formulation.
• Carbon dioxide is generally the active medicinal component when it produces the physiological or procedural effect.
• Air functions mainly as a carrier or diluent, subject to defined medical-air specifications.
• Broad composition patents are likely to be weak because the gases are established substances.
• Delivery devices, regulators, concentration monitoring, and procedure-specific methods offer stronger protection.
• FDA medical-gas CGMP requirements under 21 C.F.R. Part 213 are central to commercialization.
• Orange Book and Paragraph IV exposure depend on the specific approved product and listed patents.
• Generic entry risk is high for a commodity gas and lower for a gas-plus-device platform.
• Hospital contracting, cylinder logistics, quality assurance, and equipment compatibility may create greater commercial barriers than composition patents.
• The strongest commercial model combines a regulated gas product with proprietary delivery hardware and a defined clinical or procedural indication.

FAQs

Is carbon dioxide-air mixture the same as carbogen?

No. Carbogen generally contains carbon dioxide and oxygen, while carbon dioxide-air mixture uses medical air as the balance gas. The oxygen concentration, clinical effect, labeling, and regulatory analysis differ.

Can carbon dioxide-air mixture be patented as a composition?

A broad composition claim is difficult to sustain when the gases and their general combination are known. Patentability is more plausible for a narrow concentration range, impurity profile, packaging system, or clinically defined use.

Does the air component require pharmaceutical-grade control?

Yes. Medical air used in a medicinal gas must meet applicable quality, purity, moisture, contaminant, manufacturing, and release requirements. Ambient atmospheric air cannot automatically be treated as an acceptable pharmaceutical component.

Can a competitor sell the same gas in a different cylinder?

Potentially. If no enforceable composition, use, packaging, or device patent blocks the product, a competitor may use a different cylinder or compatible delivery system, subject to regulatory approval and applicable safety requirements.

Is a medical-gas supplier exposed to biosimilar competition?

No. Biosimilar law applies to biological products. Carbon dioxide-air mixture is a chemical medical-gas product and is exposed to generic, equivalent-product, private-label, and device-linked competition instead.

References

1. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Carbon dioxide and medical air monographs. USP-NF.

2. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia: Medicinal gases and medical air quality standards. Council of Europe.

3. U.S. Food and Drug Administration. (2020). Current good manufacturing practice, certification, postmarket safety reporting, and labeling requirements for medical gases. 21 C.F.R. Part 213.

4. U.S. Food and Drug Administration. (2017). Medical gas containers and closures; current good manufacturing practice requirements. FDA.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Orange Book.

6. United States Code. (2024). 35 U.S.C. § 154: Contents and term of patent; provisional rights.

7. European Parliament and Council. (2001). Directive 2001/83/EC on the Community code relating to medicinal products for human use. European Union.